Sugi Predict

Sugi Predict / Compounds / SCHEMBL2018569

SCHEMBL2018569

SCHEMBL2018569

CCCCCCCCCCCCCCCCCCOc1cc(COc2cc(OC)ccc2CO)cc(OCCCCCCCCCCCCCCCCCC)c1OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 3/20 0.45
▸ CNR1 P21554 1/20 0.45
▸ CYSLTR2 Q9NS75 1/20 0.40
▸ CYSLTR1 Q9Y271 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NR5A1 Q13285 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ HTR1A P08908 1/20 0.38
▸ ADRA1D P25100 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ ADRA1B P35368 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31193480 1.00 CNR2 (0.45) CNR2CNR1CYSLTR2CYSLTR1MEN1
SCHEMBL20436804 0.93 S1PR2 (0.42) CNR2CNR1CYSLTR2CYSLTR1MEN1
SCHEMBL20436812 0.91 CNR2 (0.45) CNR2CNR1CYSLTR2CYSLTR1MEN1
SCHEMBL13837222 0.88 CNR1 (0.42) CNR2CNR1CYSLTR2CYSLTR1MEN1
SCHEMBL2023354 0.88 NR5A1 (0.44) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL31614800 0.88 NR5A1 (0.44) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL2017497 0.88 CNR2 (0.53) CNR2CNR1CYSLTR2CYSLTR1MEN1
SCHEMBL22974980 0.85 APLNR (0.45) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL22974983 0.85 CNR2 (0.41) CNR2CNR1CYSLTR2CYSLTR1
SCHEMBL20436807 0.84 IDO1 (0.42) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020218497-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY 味の素株式会社 2020-10-29 — — WO claimed
US-9353147-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-9353148-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-8859732-B2 Benzylic compound AJINOMOTO CO., INC. (JP) 2014-10-14 — — US claimed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 — — US claimed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US claimed
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 — — EP claimed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 — — US claimed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 — — US disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — US disclosed
US-11939404-B2 Method for producing cyclized peptide having intramolecular S-S bond AJINOMOTO CO., INC. (JP) 2024-03-26 — — US disclosed
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY AJINOMOTO CO., INC. (JP) 2022-02-10 — — US disclosed
EP-3882255-A1 METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND AJINOMOTO CO., INC. (JP) 2021-09-22 — — EP disclosed
US-20210277063-A1 METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND AJINOMOTO CO., INC. (JP) 2021-09-09 — — US disclosed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 — — US disclosed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US disclosed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US disclosed
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 — — EP disclosed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 — — US disclosed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 CNR2 4682/4885CNR1 4670/4885CYSLTR2 3876/4885
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY VIP, NPPA, NGLY1 CNR2 4197/4885CNR1 4108/4885CYSLTR2 793/4885
US-20110160433-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN CNR2 2139/4885CNR1 2142/4885CYSLTR2 2156/4885
US-11939404-B2 Method for producing cyclized peptide having intramolecular S-S bond SPPL2B, PTMS, VIP CNR2 4671/4885CNR1 4502/4885CYSLTR2 1275/4885
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE VIP, ANPEP, NPPA CNR2 4329/4885CNR1 4353/4885CYSLTR2 2355/4885
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE ANPEP, NPPA, LNPEP CNR2 4129/4885CNR1 3645/4885CYSLTR2 3514/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 CNR2 4197/4885CNR1 4108/4885CYSLTR2 793/4885
US-20210277063-A1 METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND SPPL2B, PTMS, VIP CNR2 4671/4885CNR1 4502/4885CYSLTR2 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.